Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits

Retrovirology

Volumn 11, Issue 1, 2014, Pages 1-12

  Qin, Yali ^a   Shi, Heliang ^a   Banerjee, Saikat ^a   Agrawal, Aditi ^a   Banasik, Marisa ^a   Cho, Michael W ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

Antibody competition; eOD GT6; gp120; HIV 1 vaccine; Immunogenic epitope; Neutralizing antibody; SOSIP gp140

Indexed keywords

447 52D ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G2; NEUTRALIZING ANTIBODY; PGT121 ANTIBODY; PGT126 ANTIBODY; UNCLASSIFIED DRUG; VRC01 ANTIBODY; EPITOPE; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY COMPETITION ASSAY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP M; IMMUNOASSAY; IMMUNOGENICITY; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; RABBIT; ANIMAL; ANTIBODY PRODUCTION; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; RABBITS;

EID: 84924102247     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0125-5     Document Type: Article

References (42)

1. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
2. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, Mullins JI: Consensus and ancestral state HIV vaccines. Science 2003, 299:1515-1518. author reply 1515-8.
3. Gao F, Korber BT, Weaver E, Liao H-X, Hahn BH, Haynes BF: Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004, 3:S161-S168.
4. Ellenberger DL, Li B, Lupo LD, Owen SM, Nkengasong J, Kadio-Morokro MS, Smith J, Robinson H, Ackers M, Greenberg A, Folks T, Butera S: Generation of a consensus sequence from prevalent and incident HIV-1 infections in West Africa to guide AIDS vaccine development. Virology 2002, 302:155-163.
5. Kong W-P, Wu L, Wallstrom TC, Fischer W, Yang Z-Y, Ko S-Y, Letvin NL, Haynes BF, Hahn BH, Korber B, Nabel GJ: Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009, 83:2201-2215.
6. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T: Timing the ancestor of the HIV-1 pandemic strains. Science 2000, 288:1789-1796.
7. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, Ndung'u T, Klein I, Chang SY, Peter T, Thior I, Foley BT, Gaolekwe S, Rybak N, Gaseitsiwe S, Vannberg F, Marlink R, Lee TH, Essex M: Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol 2002, 76:5435-5451.
8. Gao F, Weaver EA, Lu Z, Li Y, Liao H-X, Ma B, Alam SM, Scearce RM, Sutherland LL, Yu J-S, Decker JM, Shaw GM, Montefiori DC, Korber BT, Hahn BH, Haynes BF: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163.
9. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao H-X, Ma B-J, Muldoon M, Theiler J, Nabel GJ, Letvin NL, Korber BT, Hahn BH, Haynes BF, Gao F: Crosssubtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 2006, 80:6745-6756.
10. Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho Z, Ma B-J, Li Y, Decker JM, Nabel GJ, Montefiori DC, Hahn BH, Korber BT, Gao F, Haynes BF: A groupMconsensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006, 353:268-282.
11. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, Hahn BH, Haynes BF, Letvin NL: A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci 2008, 105:10489-10494.
12. Liao H-X, Tsao C-Y, Alam SM, Muldoon M, Vandergrift N, Ma B-J, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia S-M, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B: Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 2013, 87:4185-4201.
13. Weaver EA, Camacho ZT, Gao F: Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. AIDS Res Hum Retroviruses 2010, 26:577-584.
14. Qin Y, Banasik M, Kim S, Penn-Nicholson A, Habte HH, LaBranche C, Montefiori DC, Wang C, Cho MW: Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence. Virology 2014, 462-463:363-376.
15. Kim YB, Han DP, Cao C, Cho MW: Immunogenicity and ability of variable loopdeleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2003, 305:124-137.
16. Julien J-P, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA: Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
17. Jardine J, Julien J-P, Menis S, Ota T, Kalyuzhniy O, McGuire A, Sok D, Huang P-S, MacPherson S, Jones M, Nieusma T, Mathison J, Baker D, Ward AB, Burton DR, Stamatatos L, Nemazee D, Wilson IA, Schief WR: Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
18. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
19. Lyumkis D, Julien J-P, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB: Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490.
20. Nara PL, Goudsmit J: Clonal dominance of the neutralizing response to the HIV-1 V3 epitope: evidence for original antigenic sin during vaccination and infection in animals, including humans. In Vaccines 91. Edited by Lerner RA, Ginsberg H, Chanock RM, Brown F. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1991:51-58.
21. Nara PL, Garrity R: Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 1998, 16:1780-1787.
22. Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J, Barrera J, Pena L, Grubman MJ, Nara PL: Deceptive imprinting and immune refocusing in vaccine design. Vaccine 2008, 26:6189-6199.
23. Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MNE, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Karlsson Hedestam GB: Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol 2009, 183:3373-3382.
24. Heap CJ, Wang Y, Pinheiro TJT, Reading SA, Jennings KR, Dimmock NJ: Analysis of a 17-amino acid residue, virus-neutralizing microantibody. J Gen Virol 2005, 86:1791-1800.
25. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A: Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010, 5:e8805.
26. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
27. Aricescu AR, Lu W, Jones EY: A time- and cost-efficient system for highlevel protein production in mammalian cells. Acta Crystallogr D Biol Crystallogr 2006, 62:1243-1250.
28. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PNP, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ: Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334:1289-1293.
29. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995, 11:533-539.
30. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, Zolla-Pazner S: Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 1992, 66:7538-7542.
31. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993, 150:635-643.
32. Conley A, Conard P, Bondy S, Dolan C, Hannah J, Leanza W, Marburg S, Rivetna M, Rusiecki V, Sugg E, Van Middlesworth F, Warne SA, Ulrich JT, Rudbach JA, Tolman RL, Emini EA: Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 1994, 12:445-451.
33. Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, McCutchan F: Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol 1995, 69:3807-3815.
34. Gorny MK, VanCott TC, Hioe C, Israel ZR, Michael NL, Conley AJ, Williams C, Kessler JA, Chigurupati P, Burda S, Zolla-Pazner S: Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade crossreactivity. J Immunol 1997, 159:5114-5122.
35. Nyambi PN, Gorny MK, Bastiani L, van der Groen G, Williams C, Zolla-Pazner S: Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol 1998, 72:9384-9391.
36. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien J-P, Wang S-K, Ramos A, Chan-Hui P-Y, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong C-H, Phogat S, Wrin T, Simek MD, Protocol G, Principal Investigators, Koff WC, Wilson IA, Burton DR, Poignard P: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
37. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, Wang S-K, Stanfield RL, Julien J-P, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong C-H, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, et al: A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
38. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A: Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein- Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10:359-369.
39. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996, 70:1100-1108.
40. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL: Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
41. Etemad-Moghadam B, Sun Y, Nicholson EK, Karlsson GB, Schenten D, Sodroski J: Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo. J Virol 1999, 73:8873-8879.
42. Crawford JM, Earl PL, Moss B, Reimann KA, Wyand MS, Manson KH, Bilska M, Zhou JT, Pauza CD, Parren PW, Burton DR, Sodroski JG, Letvin NL, Montefiori DC: Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol 1999, 73:10199-10207.